脐带间充质干细胞治疗自身免疫性肝病患者的疗效

摘要

Objective To investigate the therapeutic effect of umbilical cord mesenchymal stem cells(UC-MSCs) on the patients with autoimmune liver diseases(AILD). Methods The UC-MSCs were transplanted into 7 patients through the peripheral vein. The differences of the clinical symptoms,the index of curative effect and safety before and after treatment were compared. Results Compared with before, clinical symptoms including eating, sleep, strength and tiredness, and serum albumin (Alb), glutamate pyruvate transaminase(ALT) and glutamic-oxalacetic transaminase(AST) of all patients were significantly improved after UC-MSCs treatment (P＜ 0. 05). The total serum bilirubin(TSB), alkaline phosphatase(ALP) and glutamyl transpeptidase(GGT) were improved as well(P＞0. 05). There were no significant differences in the safety index between pre-treatment and post-treatment (P＞ 0. 05). Conclusion UC-MSCs therapy may effectively attenuate the clinical symptoms and improve the liver function in AILD patients without any severe adverse effects.%目的 探讨脐带间充质干细胞(UC-MSCs)治疗自身免疫性肝病(AILD)的疗效.方法 对7例AILD患者通过外周静脉移植UC-MSCs,分析治疗前后疗效及安全性.结果 与治疗前比较,UC-MSCs治疗后,全部患者饮食、睡眠、体力、疲劳等临床症状均有明显改善,ALB、ALT及AST明显好转(P＜0.05),Tbil、ALP及GGT亦有所改善(P＞0.05).治疗前后的安全性指标差异无统计学意义(P＞0.05).结论 UC-MSCs治疗可明显减轻AILD患者的临床症状,改善其肝功能,且安全性好.